Department of Tropical Medicine and Gastroenterology, Assiut University Hospital, Assiut, Egypt.
Saudi J Gastroenterol. 2011 Jul-Aug;17(4):245-51. doi: 10.4103/1319-3767.82578.
BACKGROUND/AIM: Both nonalcoholic fatty liver disease (NAFLD) and chronic hepatitis C virus (HCV) infection are common in Egypt, and their coexistence is expected. There is controversy regarding the influence of NAFLD on chronic HCV disease progression. This study evaluates the effect of NAFLD on the severity of chronic hepatitis C (CHC) (necroinflammation and fibrosis) and assesses the relative contribution of insulin resistance syndrome to the occurrence of NAFLD in patients with chronic HCV infection.
Untreated consecutive adults with chronic HCV infection admitted for liver biopsy were included in this study. Before liver biopsy, a questionnaire for risk factors was completed prospectively, and a blood sample was obtained for laboratory analysis.
Our study included 92 male patients. Their mean ± SD age and aspartate aminotransferase (AST) level were 42 ± 7.7 years (range 20-56) and 68 ± 41.7 U/L (range 16-214), respectively. The mean insulin level and insulin resistance index were 15.6 ± 18.3 mIU/mL (range 5.1-137.4) and 5.9 ± 15.2 (range 0.9-136.2), respectively. Fifty four percent of patients had steatosis and 65% had fibrosis. In multivariate analyses, steatosis was associated with insulin resistance and fibrosis was associated with high AST level, age ≥40 years, and steatosis.
Steatosis is a histopathologic feature in >50% of patients with chronic HCV infection. Insulin resistance has an important role in the pathogenesis of steatosis, which represents a significant determinant of fibrosis together with high serum AST level and older age.
背景/目的:非酒精性脂肪性肝病(NAFLD)和慢性丙型肝炎病毒(HCV)感染在埃及都很常见,预计它们会同时存在。NAFLD 对慢性 HCV 疾病进展的影响存在争议。本研究评估了 NAFLD 对慢性丙型肝炎(CHC)(坏死性炎症和纤维化)严重程度的影响,并评估了胰岛素抵抗综合征对慢性 HCV 感染患者发生 NAFLD 的相对贡献。
本研究纳入了未经治疗的连续成年慢性 HCV 感染患者进行肝活检。在肝活检前,前瞻性地完成了危险因素问卷,并采集了血液样本进行实验室分析。
本研究纳入了 92 名男性患者。他们的平均年龄和天冬氨酸转氨酶(AST)水平分别为 42 ± 7.7 岁(范围 20-56)和 68 ± 41.7 U/L(范围 16-214)。平均胰岛素水平和胰岛素抵抗指数分别为 15.6 ± 18.3 mIU/mL(范围 5.1-137.4)和 5.9 ± 15.2(范围 0.9-136.2)。54%的患者有脂肪变性,65%的患者有纤维化。多变量分析显示,脂肪变性与胰岛素抵抗有关,纤维化与高 AST 水平、年龄≥40 岁和脂肪变性有关。
脂肪变性是慢性 HCV 感染患者中>50%的组织病理学特征。胰岛素抵抗在脂肪变性的发病机制中起重要作用,它与高血清 AST 水平和年龄较大一起是纤维化的重要决定因素。